scholarly journals TREK-1 Mediates The Alleviative Effects of GABAB Receptor Antagonism on Depression-Like Behavior in Chronic Unpredictable Stress Rats

Author(s):  
Jinying Li ◽  
Huairui Li ◽  
Weizhi Yu ◽  
Xiuli Zhai ◽  
Hong Xu ◽  
...  

Abstract GABAB receptor (GABAB R) antagonists are known to have antidepressant effects. TWIK-related potassium channel-1 (TREK-1) plays a role in GABAB R signaling. However, the role of TREK-1 in the antidepressant actions of GABAB R antagonist is still unclear. This study aimed to investigate whether TREK-1 mediates the antidepressant actions of GABAB R antagonist. To investigate this hypothesis, chronic unpredictable stress rats were treated with a GABAB R antagonist, GABAB R agonist, or TREK-1 blocker. Depression-like behavior was assessed by open field tests and sucrose preference tests. GABAB R and TREK-1 protein levels were measured by western blotting. The results demonstrated that the GABAB R antagonist alleviated depression-like behavior and reversed the decrease in hippocampal TREK-1 protein expression that characterizes chronic unpredictable stress rats. Conversely, the GABAB R agonist exacerbated depression-like behavior and further decreased hippocampal TREK-1 protein expression. In addition, the TREK-1 blocker alleviated the depression-like behavior of chronic unpredictable stress rats and increased hippocampal TREK-1 protein expression. These results suggest that the alleviative effects of the GABAB receptor antagonist on depression-like behavior in chronic unpredictable stress rats are at least partially mediated through TREK-1. These novel findings will be helpful for the clinical therapy of depression.

Author(s):  
Priyanka Singh ◽  
Sanjay Kumar Bhadada ◽  
Divya Dahiya ◽  
Uma Nahar Saikia ◽  
Ashutosh Kumar Arya ◽  
...  

Abstract Purpose Glial cells missing 2 (GCM2), a zinc finger-transcription factor, is essentially required for the development of parathyroid glands. We sought to identify if the epigenetic alterations in the GCM2 transcription are involved in the pathogenesis of sporadic parathyroid adenoma. In addition, we examined the association between promoter methylation and histone modifications with disease indices. Experimental design mRNA and protein expression of GCM2 were analyzed by RT-qPCR and immunohistochemistry in 33 adenomatous and 10 control parathyroid tissues. DNA methylation and histone methylation/acetylation of GCM2 promoter were measured by bisulfite sequencing and ChIP-qPCR. Additionally, we investigated the role of epigenetic modifications on GCM2 and DNA methyltransferase 1 (DNMT1) expression in PTH-C1 cells by treating with 5-aza 2’deoxycytidine (DAC) and BRD4770 and assessed for GCM2 mRNA and DNMT1 protein levels. Results mRNA and protein expression of GCM2 were lower in sporadic adenomatous than in control parathyroid tissues. This reduction correlated with hypermethylation (P<0.001) and higher H3K9me3 levels in GCM2 promoter (P<0.04) in adenomas. In PTH-C1 cells, DAC treatment resulted in increased GCM2 transcription and decreased DNMT1 protein expression, while cells treated with the BRD4770 showed reduced H3K9me3 levels but a non-significant change in GCM2 transcription. Conclusion These findings suggest the concurrent association of promoter hypermethylation and higher H3K9me3 with the repression of GCM2 expression in parathyroid adenomas. Treatment with DAC restored GCM2 expression in PTH-C1 cells. Our results showed a possible epigenetic landscape in the tumorigenesis of parathyroid adenoma and also that DAC may be promising avenues of research for parathyroid adenoma therapeutics.


Stroke ◽  
2020 ◽  
Vol 51 (Suppl_1) ◽  
Author(s):  
Tongrong He ◽  
Zvonimir S Katusic

Under physiological conditions, β-site amyloid precursor protein (APP)-cleaving enzyme 2 (BACE2) cleaves APP within Aβ sequence thereby functioning like a α-secretase. However, BACE2 could also function as a conditional β-secretase during aging, contributing to Alzheimer’s disease pathogenesis. To date the physiological functions of BACE2 in endothelium are largely unknown. The present study is therefore designed to investigate the role of BACE2 in APP metabolism in human BMECs. Cultured human BMECs (passage 5-6 or passage 22) were treated with BACE2siRNA (30 nM, for 3 days), levels of soluble APPα (sAPPα, a neurotrophic product of non-amyloidogenic processing of APP) and Aβ40 in the supernatant were measured. In human BMECs (passage 5-6), genetic inactivation of BACE2 significantly decreased production of sAPPα (n=12, P<0.05), but had no effect on production of Aβ40 (n=9, P>0.05). BACE2siRNA treatment significantly suppressed APP protein expression (n=7, P<0.05), but augmented protein levels of BACE1 (n=7, P<0.05). Genetic inactivation of BACE2 did not change protein levels of mature ADAM10 (n=7, P>0.05). Thus, reduced sAPPα secretion by BACE2siRNA treatment is likely caused not only by decreased α-secretase-like function of BACE2, but also by reduced APP expression. We further examined the effects of BACE2siRNA in senescent human BMECs. In cultured human BMECs (passage 22), protein expressions of senescent markers (p 21Cip1 and p 16INK4a ) were significantly increased (n=4, P<0.05). Genetic inactivation of BACE2 in senescent human BMECs also significantly suppressed secretion of sAPPα (n=8, P<0.05), but did not affect Aβ40 production (n=8, P>0.05). BACE2-siRNA treatment significantly inhibited protein expressions of APP and mature ADAM10 (n=7, P<0.05), but did not change BACE1 protein expression (n=7, P>0.05). Thus in senescent human BMECs, reduced APP expression and impaired α-processing may play important roles in the decreased sAPPα production. Since our previous studies have demonstrated that endothelial production of sAPPα significantly contributes to the sAPPα content in the hippocampus, our current findings suggests that inhibition of BACE2 could impair protective function of sAPPα in the hippocampus.


2020 ◽  
Vol 4 (s1) ◽  
pp. 95-95
Author(s):  
Jailene Canales ◽  
Alison Weiss ◽  
Senu Apewokin

OBJECTIVES/GOALS: We previously reported that genetic polymorphisms in the beta-catenin gene (CTNNB) are associated with the development of Clostridiodes difficile colitis during autologous stem cell transplantation (https://www-ncbi-nlm-nih-gov.proxy.libraries.uc.edu/pubmed/29594489). To biological validate these findings, we sought to evaluate the development of chemotherapy-associated Clostridiodes difficile infections by assessing the effect of C.difficile toxin B (TcdB) and of using melphalan in beta-catenin protein expression in Caco2 cells. METHODS/STUDY POPULATION: To determine the effect of melphalan and/or C.difficile toxin B on expression of Beta-catenin from human gut epithelial cells: Adenocarcinoma cells (Caco-2) cells were seeded and allowed to grow into monolayersMonolayers were treated with PBS, TcdB, melphalan and/or TcdB + melphalan for 24 hours and then washed with PBSImmunofluorescence was measured on the monolayers to visualize three markers -DAPI-Nuclear Stain (blue),Actin-ccytoskeletal stain (red), B-Catenin (green)Analysis of images with ImageJ (NIH). Statistical analysis of the effect of TcdB and/or melphalan on β-catenin protein levels was determined by One-way ANOVA Cells stained with a primary anti-β catenin antibody and an Alexa-488 secondary antibody were evaluated by flow cytometry to quantify the effect of melphalan and/or C. difficile toxin B on Caco2 cells. RESULTS/ANTICIPATED RESULTS: Immunofluorescent intensity was higher in the control (PSS exposed) cells when compared to melphalan, TcdB and mephalan+TcdB exposed cells (p = 0.026, 0.004 and 0.049 respectively) DISCUSSION/SIGNIFICANCE OF IMPACT: A significant difference was seen in β catenin expression in Caco-2 monolayers exposed to TcdB and/or melphalan. These data support the a role of β-catenin in the pathophysiology of CDI during chemotherapy and support GWAS findings reporting a difference in CDI susceptibility based on β-catenin genotype.


2016 ◽  
Vol 39 (1) ◽  
pp. 183-192 ◽  
Author(s):  
Qing Li ◽  
Ji Li ◽  
Hua Shao ◽  
Xiao-Xue Li ◽  
Feng Yu ◽  
...  

Background/Aims: Our previous studies have indicated that a novel endothelin receptor antagonist CPU0213 effectively normalized renal function in diabetic nephropathy. However, the molecular mechanisms mediating the nephroprotective role of CPU0213 remain unknown. Methods and Results: In the present study, we first detected the role of CPU0213 on apoptosis in human renal tubular epithelial cell (HK-2). It was shown that high glucose significantly increased the protein expression of Bax and decreased Bcl-2 protein in HK-2 cells, which was reversed by CPU0213. The percentage of HK-2 cells that showed Annexin V-FITC binding was markedly suppressed by CPU0213, which confirmed the inhibitory role of CPU0213 on apoptosis. Given the regulation of endothelin (ET) system to oxidative stress, we determined the role of redox signaling in the regulation of CPU0213 on apoptosis. It was demonstrated that the production of superoxide (O2-.) was substantially attenuated by CPU0213 treatment in HK-2 cells. We further found that CPU0213 dramatically inhibited expression of Nox4 protein, which gene silencing mimicked the role of CPU0213 on the apoptosis under high glucose stimulation. We finally examined the role of CPU0213 on ET-1 receptors and found that high glucose-induced protein expression of endothelin A and B receptors was dramatically inhibited by CPU0213. Conclusion: Taken together, these results suggest that this Nox4-dependenet O2- production is critical for the apoptosis of HK-2 cells in high glucose. Endothelin receptor antagonist CPU0213 has an anti-apoptosis role through Nox4-dependent O2-.production, which address the nephroprotective role of CPU0213 in diabetic nephropathy.


2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Jack D. Sanford ◽  
Jing Yang ◽  
Jing Han ◽  
Laura A. Tollini ◽  
Aiwen Jin ◽  
...  

Abstract Background MDM2 is an E3 ubiquitin ligase that is able to ubiquitinate p53, targeting it for proteasomal degradation. Its homologue MDMX does not have innate E3 activity, but is able to dimerize with MDM2. Although mouse models have demonstrated both MDM2 and MDMX are individually essential for p53 regulation, the significance of MDM2-MDMX heterodimerization is only partially understood and sometimes controversial. MDM2C462A mice, where the C462A mutation abolishes MDM2 E3 ligase activity as well as its ability to dimerize with MDMX, die during embryogenesis. In contrast, the MDM2Y487A mice, where the Y487A mutation at MDM2 C-terminus significantly reduces its E3 ligase activity without disrupting MDM2-MDMX binding, survive normally even though p53 is expressed to high levels. This indicates that the MDM2-MDMX heterodimerization plays a critical role in the regulation of p53. However, it remains unclear whether MDMX is essential for the regulation of p53 protein levels in the context of an endogenous MDM2 C-terminal tail mutation. Results Here, we studied the significance of MDM2-MDMX binding in an MDM2 E3 ligase deficient context using the MDM2Y487A mouse embryonic fibroblast (MEF) cells. Surprisingly, down-regulation of MDMX in MDM2Y487A MEFs resulted in a significant increase of p53 protein levels. Conversely, ectopic overexpression of MDMX reduced p53 protein levels in MDM2Y487A MEFs. Mutations of the RING domain of MDMX prevented MDMX-MDM2 binding, and ablated MDMX-mediated suppression of p53 protein expression. Additionally, DNA damage treatment and nuclear sequestration of MDMX inhibited MDMX activity to suppress p53 protein expression. Conclusions These results suggest that MDMX plays a key role in suppressing p53 protein expression in the absence of normal MDM2 E3 ligase activity. We found that the ability of MDMX to suppress p53 levels requires MDM2 binding and its cytoplasmic localization, and this ability is abrogated by DNA damage. Hence, MDMX is essential for the regulation of p53 protein levels in the context of an MDM2 C-terminal mutation that disrupts its E3 ligase activity but not MDMX binding. Our study is the first to examine the role of MDMX in the regulation of p53 in the context of endogenous MDM2 C-terminal mutant MEF cells.


Author(s):  
Ida Marija Sola ◽  
Alan Serman ◽  
Valentina Karin-Kujundzic ◽  
Frane Paic ◽  
Anita Skrtic ◽  
...  

Dishevelled family proteins (DVL1, DVL2, and DVL3) are cytoplasmic mediators involved in canonical and non-canonical Wnt signaling that are important in embryonic development. The role of DVL proteins in the placental tissue remains mostly unknown. In the current study, we explored the role of Dishevelled proteins in naturally invasive tissue, trophoblast. Formalin-fixed paraffin-embedded samples of 15 term placentas from physiologic term pregnancies and 15 term placentas from pregnancies complicated with intrauterine growth restrictions (IUGR) were used for the study. Expression levels of mRNA for DVL1, DVL2, and DVL3 in placentas were analyzed by quantitative real-time PCR (qRT-PCR). DVL1, DVL2, and DVL3 protein expression were semi-quantitatively analyzed using immunohistochemistry. The expression of DVL2 and DVL3 proteins was significantly higher in trophoblasts in placental villi from IUGR pregnancies compared with the control group of term placentas. In contrast, DVL3 protein expression was significantly higher in endothelial cells in placental villi from IUGR pregnancies compared with normal term placentas. The observed differences at protein levels between normal and IUGR placentas were not confirmed at the mRNA levels of DVL genes. Our data indicate the active involvement of DVL proteins in IUGR-related placentas. No significant changes were observed in DVL mRNA levels between the two groups of placentas. Further studies are required to explore the clinical relevance of these observations.


Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 88-88
Author(s):  
Francisca Ferrer-Marin ◽  
Ravi K. Gutti ◽  
Zhi-Jian Liu ◽  
Joseph Italiano ◽  
Zhongbo Hu ◽  
...  

Abstract Abstract 88 Thrombopoietin (Tpo) and its receptor (c-mpl) constitute the main regulatory axis of megakaryocyte (MK) proliferation and maturation. Accordingly, adult Tpo and c-mpl knockout (KO) mice exhibit an 85% reduction in MK concentration, although the residual 10–15% MKs are ultrastructurally normal. The phenotype of newborn Tpo or c-mpl KO mice has not been well characterized, but we and others have described substantial molecular differences between neonatal and adult megakaryocytopoiesis, including several pathways that mediate the high proliferative rate of neonatal MK progenitors. Recently, two groups reported neonates with c-mpl mutations associated with congenital amegakaryocytic thrombocytopenia, who in the neonatal period exhibited normal numbers of immature appearing marrow MKs. The fact that these infants were severely thrombocytopenic at that time suggests that their MKs did not produce platelets normally. These reports, coupled with our recent observation that Tpo mediates the cytoplasmic maturation of human neonatal MKs, led us to hypothesize that, during fetal and neonatal life, Tpo-independent pathways predominantly stimulate MK proliferation, while MK maturation is Tpo-dependent. To test this hypothesis, we studied the characteristics of MKs generated in vivo in neonates in the absence of c-mpl. Since we have previously demonstrated that the liver is the main site of megakaryocytopoiesis in newborn mice, we evaluated MKs in the livers of c-mpl KO and WT mice (both C57BL/6) on day of life 1 and 3. As a first step, we quantified MKs immunohistochemically stained with an anti-vWF antibody, and found that MKs in the liver of newborn c-mpl KO mice were reduced by approx. 70%. Next, we examined the ultrastructure of these liver MKs by transmission electron microscopy, and categorized c-mpl KO MKs (n=28) and WT MKs (n=32) as stage I (immature), stage II (abundant alpha-granules and a developing demarcation membrane system, DMS), or stage III (platelet producing MKs, with an open DMS). According to these criteria, 50% of WT MKs were stage II, and 50% were stage III. In contrast, 22% of c-mpl KO MKs were stage I, 57% were stage II, and only 21% were stage III. Furthermore, significant ultrastructural abnormalities were found in 70% of c-mpl KO MKs, including decreased numbers of platelet granules, a very disorganized appearing closed demarcation membrane system, and/or an abnormally wide peripheral zone. Since MKs in adult mice mature normally in the absence of Tpo, we then hypothesized that our findings reflected a downregulation of Tpo-independent pathway(s) mediating MK maturation in neonates. In that regard, we recently found that the microRNA miR9 was expressed at 10- to 14-fold higher levels in murine fetal and neonatal compared to adult MKs. Since CXCR4 (the receptor for SDF-1) is a predicted target of miR9, and in view of recent studies characterizing the role of the SDF-1/CXCR4 axis as a Tpo-independent pathway that stimulates MK maturation, we evaluated CXCR4 protein expression in cultured MKs derived from murine fetal liver (E13.5), newborn liver, and adult bone marrow, by Western Blot. As predicted, CXCR4 protein levels were significantly lower in fetal and neonatal compared to adult MKs (p=0.003). To evaluate the significance of these findings in humans, we then quantified miR9 and CXCR4 protein levels in cord blood-derived and adult peripheral blood-derived human MKs (n=3 per group). Consistent with the murine findings, we found that miR9 levels were approximately 20-fold higher and CXCR4 protein levels were significantly lower in human neonatal compared to adult MKs (p<0.05 for both). Finally, to determine whether miR9 regulates CXCR4 protein expression, Meg-01 cells were nucleofected with miR9 or Cy3 (control). As hypothesized, up-regulation of miR9 resulted in a significant reduction in CXCR4 protein levels compared to control cells (p=0.02). In conclusion, our findings indicate that MKs in the neonatal period do not mature normally in the absence of Tpo, presumably due to a deficiency in Tpo-independent pathway(s) of MK maturation at this developmental stage. Our data also identified a developmental downregulation of CXCR4 protein expression by miR9 in fetal and neonatal MKs. Given the role of the SDF/CXCR4 axis mediating Tpo-independent MK maturation, this provides a potential mechanism to explain the c-mpl KO findings. Disclosures: No relevant conflicts of interest to declare.


Hypertension ◽  
2016 ◽  
Vol 68 (suppl_1) ◽  
Author(s):  
Anagha Sen ◽  
Prerna Kumar ◽  
Sarah H Lindsey ◽  
Prasad V Katakam ◽  
Meaghan Bloodworth ◽  
...  

The objective of the present study was to examine the repressive effect of transforming growth factor beta 1 (TGF-β1) in the regulation of Npr1 (coding for guanylyl cyclase/natriuretic peptide receptor-A; GC-A/NPRA) gene expression and vascular signaling. The rat thoracic aortic vascular smooth muscle cells (RTASMC) and denuded aortic rings were cultured in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum and treated with TGF-β1 in a time-and dose-dependent manner. Treatment with TGF-β1 decreased NPRA mRNA and protein levels by 62% (0.42 ± 0.05 vs. control, 0.9 ± 0.02, p < 0.01) and 55% (9603 ± 860 vs. control, 22211 ± 1449, p < 0.01), respectively. TGF-β1 treatment significantly increased delta EF1 (δEF1) protein expression by 2.4-fold (907.9 ± 36.5. vs. control, 378.5 ± 10.3; p < 0.001) and enhanced its recruitment to Npr1 promoter. TGF-β1-treated RTASMCs and denuded aortic rings showed significant increases in α-smooth muscle actin (α-SMA) and collagen type 1 alpha 2 (COL1A2) protein expression, which were markedly attenuated by ANP treatments. The TGF-β1-pretreated cells showed 2.6-fold increase in α-SMA (control, 1523 ± 143, TGF-β1, 3997 ± 182 and TGF-β1 + ANP, 2172 ± 135) and 3.4-fold increase in COL1A2 (control, 1250 ± 77, TGF-β1, 4234 ± 110 and TGF-β1 + ANP, 1546 ± 57), respectively. In ex vivo experiments of denuded-aortic rings, TGF-β1 decreased Npr1 mRNA and protein levels by 62% (0.39 ± 0.06 vs. control 1.10 ± 0.01) and 70% (2609 ± 69 vs. control 5775 ± 123), respectively, and significantly (p < 0.0) increased the expression of TGF-β1-responsive proteins, namely α-SMA (2.6-fold) and COL1A2 (3.1-fold). Treatment with increasing concentrations of ANP (IC50=6x10 -9 M), relaxed denuded aortic rings contracted with prostaglandin F2α (PGF2α); however, pretreatment with TGF-β1 significantly attenuated ANP-mediated vascular relaxation after PFG2α contraction (ANP-treated, 68.68 ± 9.4 vs. TGF-β1 + ANP-treated 88.85 ± 4.7). The endothelium-intact vessels were not affected by TGF-β1 incubation. Together, the present results suggest that an antagonistic cascade exists between TGF-β1 pathways and ANP/NPRA signaling, which might be critical in the vascular remodeling and regulation of hypertension and cardiovascular homeostasis.


2014 ◽  
Vol 24 (5) ◽  
pp. 851-856 ◽  
Author(s):  
Gyftaki Revekka ◽  
Liacos Christina ◽  
Politi Ekaterini ◽  
Liontos Michalis ◽  
Saltiki Katerina ◽  
...  

ObjectiveThyroid-stimulating hormone (TSH) regulates normal thyroid function by binding to its receptor (thyroid-stimulating hormone receptor -TSHR) that is expressed at the surface of thyroid cells. Recently, it has been demonstrated that TSHR is abundantly expressed in several tissues apart from the thyroid, among them the normal ovarian surface epithelium. The role of TSHR expression outside the thyroid is not completely understood. The current study examines possible alterations of TSHR expression in ovarian carcinomas and its implication in ovarian carcinogenesis.Materials and MethodsQuantitative real-time polymerase chain reaction and immunohistochemistry analysis of TSHR expression were performed in 34 ovarian carcinoma specimens and 10 normal ovarian tissues (controls).ResultsSignificant reduction in TSHR messenger RNA (mRNA) expression was detected in ovarian carcinomas (mean [SD]: 0.518 [0.0934] vs normal, 49.4985 [89.1626];P< 0.001, Mann-WhitneyUtest), whereas TSHR protein levels were significantly increased (percentage of positive cells: cancer, 73.55% [20.09%], vs normal, 54.54% [21.14%]; intensity: cancer, 2.52 [0.508], vs normal 1 [0];P= 0.012, Mann-WhitneyUtest). No significant differences in TSHR mRNA were found according to history of thyroid disease.ConclusionsOur study describes for the first time alterations in TSHR expression both at mRNA and protein levels in ovarian carcinomas. The discrepancy between the decreased levels of the TSHR mRNA and the increased protein expression has already been described in thyroid carcinomas and might be due to alterations in its degradation by the ubiquitin system or other unknown mechanisms. Further analysis could elucidate the role of these findings in ovarian carcinogenesis.


2021 ◽  
Vol 22 (3) ◽  
pp. 1403
Author(s):  
Hanon Lee ◽  
Jiyeong Lim ◽  
Jang-Hee Oh ◽  
Soyun Cho ◽  
Jin Ho Chung

Proteoglycan (PG) is a glycosaminoglycan (GAG)-conjugated protein essential for maintaining tissue strength and elasticity. The most abundant skin PGs, biglycan and decorin, have been reported to decrease as skin ages. Insulin-like growth factor-1 (IGF-1) is important in various physiological functions such as cell survival, growth, and apoptosis. It is well known that the serum level of IGF-1 decreases with age. Therefore, we investigated whether and how IGF-1 affects biglycan and decorin. When primary cultured normal human dermal fibroblasts (NHDFs) were treated with IGF-1, protein levels of biglycan and decorin increased, despite no difference in mRNA expression. This increase was not inhibited by transcription blockade using actinomycin D, suggesting that it is mediated by IGF-1-induced enhanced translation. Additionally, both mRNA and protein expression of ADAMTS5, a PG-degrading enzyme, were decreased in IGF-1-treated NHDFs. Knockdown of ADAMTS5 via RNA interference increased protein expression of biglycan and decorin. Moreover, mRNA and protein expression of ADAMTS5 increased in aged human skin tissues compared to young tissue. Overall, IGF-1 increases biglycan and decorin, which is achieved by improving protein translation to increase synthesis and preventing ADAMTS5-mediated degradation. This suggests a new role of IGF-1 as a regulator for biglycan and decorin in skin aging process.


Sign in / Sign up

Export Citation Format

Share Document